Health-related quality of life in patients with high-grade glioma

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 41-50

  Cheng, Jin Xiang ^a   Zhang, Xiang ^a   Liu, Bo Lin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cognitive function; Depression; Health related quality of life; High grade glioma; Instruments; Survival

Indexed keywords

BECK DEPRESSION INVENTORY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION; DEPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MINI MENTAL STATE EXAMINATION; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE;

BRAIN NEOPLASMS; GLIOMA; HEALTH STATUS; HUMANS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 61449228339     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-050     Document Type: Review

References (84)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc. 2007;82:1271- 1286.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
4. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334:835-840.
5. Macdonald DR, Kiebert G, Prados M, Yung A, Olson J. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest. 2005;23:138-144.
6. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton: Chapman and Hall/CRC Press; 2002.
7. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671-679.
8. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
9. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771.
10. Phillips C, Guiney M, Smith J, Hughes P, Narayan K, Quong G. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol. 2003;68: 23-26.
11. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583-1588.
12. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glio- blastoma in the elderly. N Engl J Med. 2007;356:1527-1535.
13. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007;81:287-294.
14. Levin VA, Phuphanich S, Yung WK, et al. Randomized, double- blind, placebo-controlled trial of marimastat in glioblastoma mul- tiforme patients following surgery and irradiation. J Neurooncol. 2006;78:295-302.
15. Henriksson R, Malmstrom A, Bergstrom P, et al. High-grade astro- cytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol. 2006;78:321-326.
16. Hamilton DA. Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma. Cancer Treat Rev. 2006;32:483-486.
17. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937-944.
18. Davies E, Clarke C. Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J Neurol Neurosurg Psychiatry. 2005;76:555-561.
19. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278-300.
20. Gupta T, Sarin R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol. 2002;3:557-564.
21. Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634-656.
22. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol. 1992;14:243-253.
23. Heimans JJ, Taphoorn MJ. Impact of brain tumour treatment on quality of life. J Neurol. 2002;249:955-960.
24. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5:139-150.
25. Tombaugh TN, Mclntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
26. Tangalos EG, Smith GE, Ivnik RJ, et al. The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. Mayo Clin Proc. 1996;71:829-837.
27. Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol. 2003;21:2519-2524.
28. Meyers CA, Wefel JS. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557-3558.
29. Taylor BV, Buckner JC, Cascino TL, et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol. 1998;16:2195-2201.
30. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18:646-650.
31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
32. Osoba D, Aaronson NK, Muller M, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol. 1997;34:263-278.
33. Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005;23:4936-4944.
34. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
35. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75:1151-1161.
36. Kalkanis SN, Quinones-Hinojosa A, Buzney E, Ribaudo HJ, Black PM. Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire. J Neurooncol. 2000;48:233-241.
37. Janda M, Steginga S, Langbecker D, Dunn J, Walker D, Eakin E. Quality of life among patients with a brain tumor and their carers. J Psy- chosom Res. 2007;63:617-623.
38. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28:192-211.
39. Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality- of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932-2940.
40. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol. 2000;2:221-228.
41. Locke DE, Decker PA, Sloan JA, et al. Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage. 2007;34:628-638.
42. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc. 2002;77:479-487.
43. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol. 2003;63:179-186.
44. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med. 1998;17:517-532.
45. Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002;38:1824-1831.
46. Trojanowski T, Peszynski J, Turowski K, et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg. 1989;70:18-23.
47. Pickles T, Goodman GB, Rheaume DE, et al. Pion radiation for high grade astrocytoma: results of a randomized study. Int J Radiat Oncol Biol Phys. 1997;37:491-497.
48. Bampoe J, Laperriere N, Pintilie M, Glen J, Micallef J, Bernstein M. Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment. J Neurosurg. 2000;93:917-926.
49. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34:1902-1909.
50. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853-860.
51. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002;4:39-43.
52. Hassler M, Micksche M, Stockhammer G, et al. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wien Klin Wochenschr. 2006;118:230-238.
53. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-266.
54. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000;36:1788-1795.
55. Postma TJ, Heimans JJ, Luykx SA, et al. A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol. 2000;11:409-413.
56. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin- efficacy in patients with recurrent high-grade glioma. Cancer. 2004; 100:1199-1207.
57. Addington-Hall J, Kalra L. Who should measure quality of life? BMJ. 2001;322:1417-1420.
58. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 2003;55:992-999.
59. Sneeuw KC, Aaronson NK, Osoba D, et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care. 1997;35:490-506.
60. Mainio A, Hakko H, Niemela A, Koivukangas J, Rasanen P. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry. 2006;21:194-199.
61. Rogers MP, Orav J, Black PM. The use of a simple Likert scale to measure quality of life in brain tumor patients. J Neurooncol. 2001;55:121-131.
62. Weitzner MA, Meyers CA, Byrne K. Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg. 1996; 84:29-34.
63. Hom J, Reitan RM. Neuropsychological correlates of rapidly vs. slowly growing intrinsic cerebral neoplasms. J Clin Neuropsychol. 1984;6:309-324.
64. Taphoorn MJ, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48-54.
65. Klein M, Taphoorn MJ, Heimans JJ, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19:4037-4047.
66. Salo J, Niemela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients' perceived quality of life. J Neurol Neurosurg Psychiatry. 2002;72:373-377.
67. Levine DN, Grek A. The anatomic basis of delusions after right cerebral infarction. Neurology. 1984;34:577-582.
68. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996;74:1674-1679.
69. Giovagnoli AR, Tamburini M, Boiardi A. Quality of life in brain tumor patients. J Neurooncol. 1996;30:71-80.
70. Choucair AK, Scott C, Urtasun R, Nelson D, Mousas B, Curran W. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1997;38:9-20.
71. Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562-568.
72. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57:41-49.
73. Litofsky NS, Farace E, Anderson F, Jr., Meyers CA, Huang W, Laws ER, Jr. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery. 2004;54:358-366.
74. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psychiatry. 1999;67:358-363.
75. Kirshblum S, O'Dell MW, Ho C, Barr K. Rehabilitation of persons with central nervous system tumors. Cancer. 2001;92(suppl):1029-1038.
76. Brown PD, Jensen AW, Felten SJ, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427-5433.
77. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology. 1997;6:169-177.
78. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003;5:89-95.
79. Browne JP, O'Boyle CA, McGee HM, et al. Individual quality of life in the healthy elderly. Qual Life Res. 1994;3:235-244.
80. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12:608-616.
81. Mauer M, Stupp R, Taphoorn MJ, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblas- toma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97:302-307.
82. Sehlen S, Lenk M, Hollenhorst H, et al. Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neo- plasma during radiotherapy. Onkologie. 2003;26:38-43.
83. Klein M, Postma TJ, Taphoorn MJ, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology. 2003;61:1796-1798.
84. Mainio A, Tuunanen S, Hakko H, Niemela A, Koivukangas J, Rasanen P. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci. 2006;256:516-521.